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RESUMO
O artigo trata da transferência de Biotecnologia em um confronto 
com a transferência geral de tecnologia e do reconhecimento do regime 
das obrigações de meio e resultado nos contratos que tenham como objeto 
tecnologia a ser cedida. 
Palavras-chave: Contrato, Tecnologia, Obrigação, Meio, Resultado.
RESUMEN
El objetivo del estudio ha sido abordar la transferencia de biotecnología 
en una confrontación con la transferencia general de tecnología y el 
reconocimiento del medio y las obligaciones de resultado en los contratos 
cuyo objeto es la tecnología que se asignará..
Palabras clave: Contrato, Tecnología, Obligación, Medio, Resultado.
INTRODUCTION 
1ST PART - BIOTECHNOLOGICAL KNOWLEDGE
1.1 Biotechnology
1.1.1 Notion
Every technological application directed to Biology is 
a biological technology and from this phrase, the term 
Biotechnology originates. And all Biotechnology experts 
record and develop carefully, sometimes more sometimes 
less, their material object. They do so with the clarifica-
tion that there is no emphasis on the subject of scientific 
categorization and merely construct its content or the 
field in which it will be applied.
In the embryonic forms of Philosophy of Science, but 
without conclusive results, much has been debated, even 
in specialized literature, regarding the scientific characteri-
zation of Biotechnology. Because of the effects it provides 
and the fact that it bears something different compared 
to other forms of knowledge, certain doubts reign among 
experts. The uniqueness grows by the scientific impulse 
that it causes and the impact on modern life. However, 
biotechnology is not a new branch of science. The fact 
that the authors do not harmonize in its configuration, 
leading to theoretical explanations that even approach the 
contradictions, and only extend the field of imagination. 
More recently, there is an orientation that, even without 
the consistent support of the writers, deserves greater 
emphasis: that Biotechnology is nothing more than a set 
of amalgamated technologies. Nonetheless, the practical 
importance of this discussion should not be denied, espe-
cially if one considers the general and integral purpose 
of science to consistently expand the rational activity of 
the human being and to free it from spontaneous forces 
through the passing of the almost irrational problems of 
nature in rational processes.
In a broad sense, and given its conclusive line of 
evolution, Biotechnology can be defined as the use of 
living organisms or parts of them (subcellular structures 
or molecules) for the production of goods and services. 
Although based on a double reductionist perspective 
(living organisms or parts of them and the production of 
goods and services), this definition encompasses a set of 
activities that man has been developing for thousands of 
years, such as the production of fermented foods. Also, 
it is in this line of reasoning that modern biotechnology 
is considered to be that which, considering the definition 
in double perspective, makes use of genetic information, 
incorporating techniques of recombinant DNA (known 
as deoxyribonucleic acid). 
Over time and with the development of biological 
technologies, Biotechnology has become, in its purity, 
a discipline of intensive scientific advance, with inter-
disciplinarity unparalleled with other disciplines, and 
associated with strong links of complementarity with 
other technologies. It would not be absurd to report that 
the civilization of our time would find real stagnation in 
everyone’s livelihood if the complexity of its archetypes 
were altered. While this specificity is emphasized, an 
economic function has been determined among the 
companies that are linked to it: the constant need for 
innovation, new product launches, and technology deve-
lopment. These characteristics, encompassed by those of 
necessity in the present world, return to the premises that 
without Biotechnology, individual life would regress by 
limiting man’s activity to its primary moments. Parallel 
to the economic function, there is another civilizing in 
itself, and, why not say, educational in nature. It brings 
men closer and bridges the differences. While the indi-
vidual admits the possibility of obtaining what is nee-
ded for the transformations of the world, it was able to 
sharpen its sense of scarcity, which only gained in scope 
when geographers and statisticians persuaded everyone 
to observe the limits of natural inputs in the constant 
effort of progress and the attainment of an era marked 
by food, health, and environmental harmony. 
Therefore, Biotechnology itself is a source of effort 
that should guide research and development activities 
to discover new applications and generate synergies with 
other areas, despite the challenges of new problems and 
the costs of technologies. However, one must beware of 
the uncertainties and risks of the early stages of develop-
ment of biological technology, the eventual failure or even 
failure of research. All the vigor of an area where a huge 
variety of outcomes is desired can be left in vain if those 
results are late or do not achieve their expected effects. 
1.1.2 Biotechnology Technology 
Without repeating here what has already been exposed 
in the places indicated, one should refer, however brie-
fly, to the use of the terms and some basic definitions. 
And this is done by recent advances in biotechnological 
inventions. Even if they correspond to traditionally used 
terms, the best thing to do is to repeat the subject with a 
series of clarifications and to define terms and concepts.
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In its Greek etymology (of bios, life), Biotechnology 
refers, roughly, to technologies that utilize living orga-
nisms. If the previous premise is a peaceful point, perhaps 
in its generality, a more precise definition would not find 
such uniformity.
The Committee on Biotechnology and Industrial 
Property Specialists of the World Intellectual Property 
Organization, at its February 1986 session in Geneva, 
commented on the significance of Biotechnology: “Bio-
technology encompasses all techniques using living orga-
nisms, in particular, animals, plants and microorganisms, 
or any kind of biological material that can be assimilated 
to microorganisms or parts thereof, to bring about organic 
changes in them”.
Considering the situation of this research, in which 
the technical word is determinant, it should be remem-
bered that reference is made basically to genetics, micro-
biology, biology, and biochemistry, and their fields of 
application are directly related to agriculture, chemistry, 
pharmaceutical industry, health, food production, and 
environmental conservation.
Another clear and detailed definition is proposed by 
the United States Congress Office of Technology Asses-
sment in its second report of 1984, which states that 
“biotechnology comprises all techniques that use living 
organisms (or part of them) to manufacture or modify 
products, to improve plants or animals, or to develop 
microorganisms for particular uses”.
The living organisms used in biotechnology are:
(a) Organisms in their natural state;
(b) Organisms obtained by conventional means of 
selection, cross or mutation;
(c) Organisms modified by new techniques.
Examples of organisms in their natural state are 
microorganisms used in fermentation processes. Examples 
of organisms obtained by conventional means of selection 
are essentially biological procedures. And finally, there are 
examples of organisms modified by new techniques such 
as genetic engineering or cell fusion technique.
Biotechnology can then be classified into four groups:
1) Living organisms;
2) The procedures for obtaining living organisms;
3) Procedures using new and known microorganisms;
4) The products obtained with these procedures.
Living organisms mean animals, plants and microor-
ganisms. Microorganisms are defined as all living micros-
copic beings that are naturally occurring or obtained by 
conventional methods or new techniques. And within 
the microorganisms are included, among others, viruses, 
bacteria, fungi, and algae.
The procedures for obtaining living organisms can be 
divided into two classes:
1) Conventional methods;
2) The unconventional or new methods.
Selection, cross and mutation methods are conven-
tional. Genetic engineering or cell fusion technique is 
unconventional or new methods. The essential difference 
between the so-called conventional or traditional methods 
and the unconventional or new methods lies in the pos-
sibility that the latter, through manipulation of hereditary 
material, overcome pre-existing biological barriers, such 
as incompatibilities between species. It should be noted 
that these methods are not ends in themselves, but are 
intended for obtaining useful products through such 
living organisms or cell cultures.
Moreover, it is not too much to remember that the 
selection technique was the first one that was used to 
improve plants and animals. This is how, over time, more 
elaborate techniques were introduced, such as cross dif-
ferent genotypes, cross pedigrees and mutations, which 
consist of using physical or chemical means to bring 
about changes in a genotype. And it is possible to modify 
the genes of plants, animals, and microorganisms by 
introducing artificially modified hereditary material. The 
mutation technique is also used to obtain new microor-
ganisms. This happens with the application of new or 
unconventional methods to obtain living organisms, and 
it is within these methods that genetic engineering and 
the technique of cell fusion stand out.
Genetically engineered is the technique of recom-
bined DNA, and consists of isolating a gene from its 
natural context and using it in such a way that, at the 
biological level, a quantity of it (or chemicals) can be 
obtained practically unlimited. This is accomplished by 
the steps of isolating or separating a DNA fragment, 
inserting that fragment into a recombinant vector, intro-
ducing the recombinant vector into a microorganism or 
a “host” cell to obtain a recombinant cell, selecting the 
recombinant cells and provoke its activity under condi-
tions favorable to gene expression, and thus obtain the 
desired product. And from this one obtains, for example, 
insulin and interferon.
The cell fusion technique consists of fusing two cell 
types that have a particular characteristic and selecting 
cells that have characteristics of both types and used cells. 
This technique is used to improve plants and to produce 
hybridomas, monoclonal antibody producers. 
1.1.3 Applications 
This new technology improves overall well-being and 
enhances competitive advantages, especially in the phar-
maceutical and chemical sectors, in order to generate 
consequences, for example on agriculture and food, as 
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well as environmental effects. It can also be argued that 
the integration of biotechnology with this wide range 
of sectors was not uniform, but it can be said without 
a doubt that the pharmaceutical sector is the conside-
rable part in which biological technology continues to 
predominate.
In a great diversity of plans and orientations, it should 
be said that modern biotechnology has developed and 
enriched the distinct roles of the production factor pro-
cess. And in our day, and why not say promisingly that 
in the future, it could be the core technology, capable 
of fulfilling a key function or supporting technology, in 
securing new life forms.
Undoubtedly, ontological proximity to the develop-
ment and application of new technology is the existence 
of social, economic and even environmental transforma-
tions. And these important and peculiar consequences, 
although, advance, and offer much more conditions for 
the emergence of new types of relations between eco-
nomic agents and forms of alteration and improvement 
of the productive forces and, one could not forget, a 
situation undeniable advantage, which is improved per-
formance in competitive capacity in the relevant market. 
It is also necessary to state that these social consequences, 
especially human living and health conditions, have real 
mutations, since they tend to improve the achievements 
and development of the population, in a uniform har-
mony and in broad dynamism, with economic results 
and general social.
By looking at the way of life of the people in present 
times, a determined set of methods, types, and forms of 
activity contribute to concrete general well-being, such 
as the discovery of new vaccines for human diseases and 
genetic engineering to reduce the transmission of animal 
diseases. And with the same synthesis that we dealt with 
in the previous questions, it should be remembered that 
the essences of these new ideas offer, in environmental 
terms, the instruments for the development of activities 
widely considered in a sustainable way, such as the pro-
tection of natural resources and biodiversity. Through 
so-called prevention or bioremediation strategies, sus-
tainability will find vast circles of influence beyond all 
other forms of permanence and preservation.
The central postulate is that Biotechnology provides 
a change in the state of affairs and substantial changes 
in incremental effects, and in its own time and under 
appropriate conditions what would be true disruptive 
attitudes, or even radical inclusions, despite knowing that 
the latter are rare and infrequent, though unpredictable. 
In this sense, it should be noted that each of these effects 
entails a challenge that can underpin a variety of public 
policies in the mean and long term.
1.2 World and regional panorama
1.2.1 History
Modern biotechnology, that is, the thinking of bio-
logical technology of the most recent period of science, 
originates in the United States of America. This country 
(USA) was the pioneer in the development of biotechno-
logy and is still the undisputed leader in this field. And 
yours are also the first companies to form in this sector, 
from the late 1970s to the early 1980s. Outside of the 
North American space, one can mention European com-
panies, established in the 1990s, with the characteristic 
of being small or medium compared to US counterparts.
It will not be difficult to overstate the influence of US 
research worldwide, as the United States still dominates 
this knowledge in all its most well-known segments: plant 
and animal genetics, food, and medicine. These three 
areas focus on an interinstitutional complex set up on a 
tripod: public laboratories, universities, and biotechno-
logy companies. Europe reproduces this model and, with 
less emphasis on public laboratories, Japan, and China. 
The United States of America, Europe, and Japan made 
public expenditures directed specifically at the health 
sector (public spending on biotechnology research and 
development in 2005: US$ 23 billion; European member 
countries of the Organization for Economic Co-operation 
and Development (OECD) $ 4 billion and other OECD 
member countries $ 1.5 billion.
And it is already predicted that for the year 2030 the 
applications of the sector analyzed could represent about 
3% of the Gross Domestic Product (GDP) of OECD cou-
ntries. In absolute terms, this percentage will be higher 
than the GDP of developing countries. This data does 
not include the future impact of biofuel use on develo-
ped economies.
So profound is the transformation of Biotechnology 
in the modern world that even economic crises have 
not generated major decreases in its research and deve-
lopment. These changes in the economic situation have 
encouraged cost rationalization and increasingly concen-
trated activity. It is extremely difficult to draw a complete 
picture, but it should be noted that for small and medium 
enterprises the practical result has been an increase in 
research and development capacity and an increase in 
their productivity.
The peripheral and regional economies, which belate-
dly aroused to the impact of biological technology, found 
and established their space by accelerating important 
aspects of the biotechnology industry, such as the phar-
maceutical, chemical, food, and agricultural industries. 
These activities were developed by technology transfer, but 
today some of them already maintain the development of 
cutting-edge activity in some sectors, such as India and 
Brazil, if we do not consider the Far East anymore and 
Israel as peripheral economies. Brazilian biotechnology 
institutions and companies benefit directly or indirectly 
from Brazil’s surplus effort in agribusiness. It seems to 
be said that, despite Brazil’s agricultural turnover, bio-
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tech companies are still small compared to foreign ones, 
but they already have some technical excellence and are 
closely linked to science and technology systems. Heal-
th-related research in Brazil had a notable impetus from 
the initiative of public universities, research institutes, and 
government companies, including the Empresa Brasileira 
de Pesquisa Agropecuária (Embrapa) [Brazilian Agricul-
tural Research Corporation].
Molecular biology and its application to the produc-
tion of diagnostics, vaccines, and therapeutic agents have 
received much attention, especially for tropical diseases, 
but undeniably agriculture has been the most successful 
in comparative results. It should be recognized that the 
Brazilian government has made efforts to promote biote-
chnology, not only to meet public health claims, but also 
with the ultimate goal of stimulating industrial develo-
pment. It is not possible to indicate the characteristics 
of the Brazilian private sector, given its dynamism and 
business concentration, but a special distinction should be 
highlighted: the creation of poles, parks as biotechnologi-
cal centers in all five geographic regions of the country. 
1.2.2 Biological technology and its importance in today’s 
world
If we dispense with the natural improvement, evolu-
tion, and progress of humanity in its social and economic 
achievements, scientific and technological knowledge are 
essential elements of the reflection of the real evolution 
of the world. Moreover, they serve to achieve an advan-
tageous position in all the concrete content of aspects 
of the historical trajectory of human development. It is 
quite understandable to think of an area in which no 
manifest form of technology is present, and this goes 
from simple, everyday operations such as paying for a 
public transport service, to nuclear power generation or 
space exploration. It is to be understood that this whole 
set of technological knowledge represents a very high 
value, not only strategic and political, but also economic, 
therefore, susceptible of being the object of commercial 
business, which, thanks to its potential repercussions 
on society, will be, to a greater extent or a lesser extent, 
the form of transition from the boundaries of science 
from good from the purest abstract point of view to the 
concrete point of view.
Reality is not limited to just this kind of contradic-
tion (abstract and concrete), especially on such a broad 
subject as Biotechnology. But it is necessary to remember 
that internal contradictions preside over the object of a 
research and the process of its knowledge.
If the research was to be deepened in one of the ways 
of the sciences in general, we would have to fork other 
contradictory and useful aspects for the study of tech-
nology supply, besides the above mentioned abstract and 
theoretical points of view, such as those that would be 
simple and complex, the general and the particular, or 
the static and the dynamic, if we consider only some 
aspects of the connection of the sciences.
1.2.3 Biotechnology in the world
Biotechnology can be understood as genetic engi-
neering and particularly as manipulation of recombined 
DNA. Even in different areas, such as traditional tech-
nologies such as pharmaceutical technology, which keep 
living organisms involucible and which can normally 
reproduce, which causes some disturbance very early 
in the evolution of laws and the fact that many of the 
products and processes that are patentable are derived 
from natural products and processes.
Once again, we note that Biotechnology refers to tech-
nologies that utilize living organisms. And the technical 
word refers to genetics, microbiology, biology and bioche-
mistry and their fields of application, which are related 
to agriculture, chemistry, the pharmaceutical industry, 
health, food production and the conservation of envi-
ronment.
Living organisms used in biotechnology are living 
organisms in their natural state (such as organisms used 
in fermentation processes), organisms obtained by con-
ventional means (the essentially biological procedure) 
of selection, cross-breeding or mutation, and organisms 
modified by new techniques such as genetic engineering 
or the cell fusion technique.
1.2.4 The concentration of biotechnological knowledge
Scientists and researchers seem to see with lucidity the 
peculiar character of biotechnology, and its fundamental 
difference in the framework of general knowledge. This 
intensely felt and strongly expressed scientific insight has 
enabled, especially a group of countries, to successfully 
meet the challenge of the well-being of the peoples and 
the dominant needs of our civilization. It is at this point 
that one asks about the material needs of the individual 
and the ability to provide practical and useful results to 
meet them. Without going into detail, the concentration 
of biotechnological production and knowledge represents 
one of the most discrepant or contradictory features of the 
progress and improvement of conditions in modern life. 
And it is based on this premise of contradictory success, 
which draws from objective facts how much research 
and development efforts and expenditures are polarized 
and, in turn, how considerable the lack of homogeneity 
between technology producing and consuming countries. 
Experience teaches us that everything changes, and that 
nothing is stable in the field of scientific and technologi-
cal knowledge. However, whether due to developmental 
differences before the current knowledge itself, the lack 
of research funding capacity or the support of a research 
team, this multicolored division of the use of technology 
is reduced to a few shades when it comes to knowing 
who produces the knowledge. From a benefits standpoint, 
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technology reaches everyone, but it is not structured and 
evenly matched by the small group of countries that have 
met the challenges of the practical results of mastering 
technological tools. Under the influence of this contra-
dictory premise, we note that only 15% of world produc-
tion comes from most technological innovations in the 
world, while less than half of the world’s population is can 
adapt these technologies to production and consumption. 
And even one can say that the rest of the population, 
or one-third of the world’s population, is technologically 
isolated, unable even to adapt foreign technologies or 
even to initiate research and development of its own.
In a summary, which might well bear the quality of 
an overview of the production of biological technology, 
the formation of the fundamental ideas of biotechnology 
was not only for scientific progress but also for forging 
a unique and privileged situation. It has become a real 
paradox in the appearance of the fundamental principles 
and ideals of scientific explanation, incompatible with 
the tradition of accelerating progress by promoting and 
disseminating technological advances. The purpose of 
scientific creation changes to become an economic con-
cept interest in its accelerating movement of scientific 
progress, and to generate more concentrated knowledge. 
Summarizing this economic effect, the course of transfor-
mations of science instruments and experiments would 
include not only the rise of general well-being but the 
economic concentration of technology. Alongside the 
common fundamental features of concentration of pro-
duction and technological development, the production 
of biotechnological knowledge occupies a peculiar posi-
tion because it has fewer representatives than the list of 
technology-producing countries in general.
Finally, if in general technological production it is 
a small part of the world that produces knowledge, the 
knowledge of biotechnology is limited to a few coun-
tries. There are reasons to think of a solution to these 
problems, but there is also reason to recognize the disin-
terested attitude of institutions in biotechnology research. 
This would mean underlining the lack of frameworks or 
resources for investments in research and development, 
but one can equally attribute this to the neglect or disdain 
with which the purposes of national development are set 
by each society. Acceptance of these statements implies 
facing seemingly insoluble problems. On the other hand, 
how to come up with other results if the United Nations 
Conference on Trade and Development (UNCTAD) under 
study has found that only nine OECD countries concen-
trate 90% of world spending on new technologies, while 
the share of developing countries spending on research 
and development represents only 6% of world spending?
1.2.5 The high cost of biotech production
Technological production is associated with processes 
of innovation, research, and development, which entail a 
high economic cost that, in most cases, can only be assu-
med by those who have sufficient resources to meet these 
demands. Regrettably, industrial property - the discipline 
in charge of protecting new developments - has not only 
not solved this problem, but in some way has caused 
it to worsen or damage itself. The paradigmatic exam-
ple of this situation lies in the invention patent system, 
which within this discipline represents the most common 
way of protecting technological knowledge. Due to the 
principle of territoriality that governs the protection of 
industrial property, the holder of a new technology that 
can be protected, through the patent system, must go to 
as many territories as they want to exclusively explore 
the invention in each of them and carry out the admi-
nistrative procedure to achieve the grant of the patent. 
To this end, it will be necessary to pay official fees that 
each country sets, plus the professional fees of a local 
agent, who represents them in the registration process.
These peculiarities that are considered added, together 
with the high costs of research and development, asso-
ciated with the protection of the results of these activi-
ties lead, in most cases, holders of intellectual property 
rights over biotechnological knowledge are companies 
with important power, either because they have deve-
loped their technology or because they have acquired 
rights contractually.
In addition to the above, another effect that genera-
tes the high-cost state of production and protection of 
technological knowledge is that their contribution to the 
recipient country’s production scheme is minimal, due, 
on many occasions, to the processes of adaptation of con-
ditions local authorities assume an additional economic 
effort to acquire technological knowledge. This informa-
tion was collected in a UNCTAD document presented 
in the course of negotiations on the International Code 
of Conduct on the Technology Transfer, which sets out:
 “The dependency of developing countries is considera-
bly higher and the contribution of acquired technology is 
lower than for other final technology importing countries 
because developing countries do not, in most cases, have the 
capacity for organization, research, and engineering to be 
able to adjust, adapt, and assimilate imported technology 
to their own needy.”
PART  2ND TECHNOLOGY TRANSFER
2.1 Notion
By technology transfer is meant a complex displace-
ment of situations, in which the material object is tech-
nological knowledge. Jurists seem to take the idea of 
transfer as covered by the contractual theme. Thus, they 
often employ the technology transfer figure as associated, 
or even a class of contract, with the technology transfer 
contract. Some authors go beyond the technical function 
of the contract and use the license agreement broadly to 
refer to the grant made by a patent holder, utility model, 
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technical assistance or even industrial secret. Some prefer 
a more restricted meaning and use the figure as a license 
agreement. The lack of harmonization does not preclude 
the recognition that these contracts are all mixed or rela-
ted (since the associated does not form a new contractual 
species, as occurs with the mixed), with variations in 
unknown numbers.
In these contracts, an assignee is granted the necessary 
knowledge to compose the technology to be used. They 
are usually accompanied by a series of provisions on the 
conditions required by the assignor, including the quality 
and use of the trademark. Equally ordinary is the most 
well-known remuneration in its Anglo-Saxon version of 
royalties. Royalties would correspond, according to the 
specialized literature, to the term realties, in Portuguese, 
which is used in this text.
2.2 Most common clauses in technology transfer agree-
ments
The mixed or related nature of technology transfer 
agreements does not preclude the formation of a common 
core of provisions resulting from their purpose, although 
the parties are convinced that other clauses may be placed 
on the business.
Among the known clauses is the following:
(1) Determination of assignor’s duties;
(2) The duties of the assignee;
(3) Temporal character of technology: definitive or 
temporary;
(4) Form of payment;
(5) Currency unit;
(6) Bases for the calculation of royalties;
(7) Tax effects on the transfer;
(8) Duration of the contract;
(9) Indication of the minimum (or maximum) pro-
duction of products generated by the technology;
(10) Limitations and conditions for the use of tech-
nology;
(11) Market in which the assignee may act;
(12) Technical assistance to be provided to the assig-
nor;
(13) Duty to preserve technology secrecy;
(14) Requirements as to how to employ the tech-
nology;
(15) Quality of materials to be used;
(16) Quality of goods produced;
(17) Guarantees and penalties for breach of contract;
(18) Causes for termination of the contract;
(19) Retrocession of all developed technology;
(20) Designation of the forum competent to settle 
the conflict;
(21) Arbitration prediction.
2.3 The obligations of means and result
The course of development of the legal sciences, as 
of all science in general, reveals itself in different ways, 
in equally different historical stages. And one trend is 
toward technology transfer in the form of contractual 
obligations: the obligations of means and results.
To elaborate a system of communication between 
creditors and debtors, the Law is based on relative forms 
and marked by an economic content. This explains the 
obligation directly and objectively. The question then 
immediately arises: What is the relationship of the obli-
gation to technology transfer agreements?
There would be many ways to respond. One would 
then have to ask if an agreement would not be a source 
of rights and duties for the contracting parties? And the 
statement of the answer explains, according to many opi-
nions, that these rights and duties related to the parties 
are precisely the obligations.
The French jurist Demogue was responsible for the 
theoretical construction of the idea of obligation most 
peculiar to the technology transfer contract: the obliga-
tion of means and result. His self-enunciating form of 
classification highlights that in the obligation of result, 
the execution is reached when the debtor fulfills the final 
objective; while that one in the middle, the deviation of 
certain conduct or omission in certain precautions com-
mitted by the debtor not to achieve the expected result.
Therefore, in a technology transfer, the agreement 
carries the corresponding purpose of successfully assig-
ning the product of negotiation: technology. And in 
favor of this scheme is the common thinking that if the 
technology was not transferred, the contract would have 
been frustrated in its purpose. Much work related to 
technology transfer contracts builds on this true moving 
condition to achieve the end result of the business.
Under the above conditions, the transfer of biotech-
nology should also be a use of two-way correspondence 
of the obligatory consequences of this theoretical cons-
truction as used in the commercial world, such as the 
technology transfer agreement.
As it turns out, there is a certain similarity between 
the effects of the technology transfer agreement and 
the biotechnology transfer agreement, since both seek 
the same thing, that is, a result. And a combination of 
ideas from one contract and another would lead to a 
common formation and direct use of all the experience 
already known and used in technology transfer contracts 
in general.
The difference is only that the biological chain on 
which Biotechnology is based may not be realized. The 
combined formation of the decisive elements for the out-
come may not occur. And this is evident by the different 
conditions of climate and temperature, among others, in 
the generation of concrete results, expected by the appli-
cation of a contract with obligations, markedly the result, 
as occurs in the common cases with technology transfer.
105J. res.: prop. intelec. online 2019/2020 Sep./Fev. 2(2): 98-110
Fontes ARC. Biotechnology Transfer ...
If the pluralism of life is known, and we know that 
the environment is as complex as the other known com-
plexities, it seems to be a mistake to solve the problem of 
biotechnology transfer without ignoring the mechanical 
and organic antithesis and something alive and something 
that has no life.
Life stands before itself and nothing but death. If there 
is no life, there is powerlessness and inanity. It is in this 
comfortable antithesis of the organic and the mechanical 
that all unfolding must take place. The mechanical view 
of technology transfer does not lead to adherence to the 
use of the result obligation under the general qualitative 
conditions for the quantitative probability conditions of a 
biotechnology transfer. An example would be the arrange-
ment of the structure of a certain type of microorganism 
to be used in climatic conditions different from its origi-
nal formation. And that outcome will depend more on the 
conditions required for an appraisal of middle obligations 
than on outcome. It is that without the expected effort, 
the result may not occur, unlike the result even the effort 
to achieve it was the most common and average, under 
the conditions of the contract. This is how a factory can 
be already assembled with prefabricated elements and 
achieve the result with the satisfactory operation of the 
machines. 
PART 3RD TRANSMISSION OF BIOTECHNOLOGICAL 
KNOWLEDGE
3.1 The importance of technology transfer for knowledge 
diffusion
Technological promotion and its consequent deve-
lopment are the real priorities in a technology assign-
ment. And the most abbreviated way of not returning 
to the early days to achieve state-of-the-art results is by 
providing technology already produced. Otherwise, all 
research and development would have to repeat the most 
elementary moves in succession to achieve the knowledge 
required in competitive markets, such as the consumer 
in present times. This policy of an original knowledge 
construction would require large and continuous invest-
ments, which may very well be solved with an equivalence 
of technological knowledge attainable through a transfer.
Also, companies competing in a given relevant mar-
ket expect to benefit from the lower cost compared to 
research and development spending on new products. 
Business risks are not usually accompanied by origi-
nal knowledge production initiatives, but rather by the 
relentless pursuit of profits in their endeavors. This result 
that adjusts benefit costs is regularly resolved by acquiring 
someone else’s technology through a negotiated transfer. 
                                          
3.2 The social function of biotechnology transfer processes
Technology transfer implemented through the license 
transfer agreement may have more than just economic 
significance, reaching the possibility of fulfilling a social 
function. This view has been reflected in different norma-
tive texts and harmonization initiatives. A clear example 
of this social vision can be found in Articles 7 and 66 of 
the Agreement on Trade-Related Aspects of Intellectual 
Property Rights, better known by the English acronym 
TRIPS.
It is collected in a report from the Working Group on 
Trade and Transfer of Technology to the General Cou-
ncil of the World Trade Organization (WTO), where 
the social projection of technology transfer processes is 
manifested, stating that they constitute one of the excel-
lence mechanisms for improving living conditions in 
developing countries.
The arguments outlined above serve to illustrate the 
social function of technology transfer processes that, as 
supported by pronouncements from different international 
institutions, become a powerful tool for achieving the 
goal of improving the economic and social conditions 
of countries with a lower degree of economic and tech-
nological development.
3.3 The agreement as a means of diffusing technology 
transfer
The historical-cognitive basis of modern agreements 
goes back to the period of Roman civilization, which not 
only structured the figure of the contract, but defined it 
with the main feature to be used in this text: that it is an 
agreement of wills on the same point. The importance of 
remembering this highest valuation of will is that once 
the contract is concluded, with the observance of the 
formalities of style, the contract will be able to generate 
obligations - a factor of the most essential essentiality, 
without which there would be no rights and duties of 
the parties.
Notwithstanding the formal rigor of contractual forms, 
over time and the development of activities in general, 
the function of the agreement has changed, and without 
losing its purity and structure, it has shaped interests in 
the complexity of life in our times, without changing 
their binding force.
Without the agreement, homo economicus would stop 
its activities, because it is the agreement that provides 
for everyone’s livelihood, without which individual life 
would regress, and man’s activity would be limited to 
the primary moments of the human course.
Another virtue to consider. Alongside the economic 
function, the agreement serves as a civilizing and deve-
lopmental form. It is the agreement that promotes the 
circulation of wealth, brings men closer and reduces dif-
ferences by providing everyone with legal instruments 
to achieve the ends determined by economic interests, 
and why not say, the interests of society as a whole. All 
that remains to be remembered is that it is through the 
agreement that technology develops and propagates.
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It is through contractual forms and obligations that 
advances in technology spread. And all of this is reflec-
ted in the idea that an agreement of wills can force one 
person to give in to another to take advantage of their 
knowledge of a special manufacturing process, original 
or only known information or practice.
For the analysis, clarification, and solution of the 
transmission of knowledge, it should be pointed out 
that it occurs by simply handing over plans, drawings or 
other papers, by providing the material that incorporates 
the knowledge or, finally, by the practical teaching of its 
application, either by means of technicians sent for this 
purpose, or by the admission, in its own factory, of people 
designated to learn, practicing the manufacturing process.
3.4 Difficulties encountered in intellectual property for 
technology transfer processes
The unfolding of the whole field of knowledge and 
human activity also found its reflexes in the elaboration 
of the legal principles that guide the construction of a 
system of protection of the rights that would result from 
the development and improvement of the goods resulting 
from all the effort and work.
The discipline of intellectual property adopts a plura-
lity of techniques and instruments to protect the interests 
of their owners. There is no doubt that there is not just 
one but many forms of intellectual property protection. 
And in all of them, one speaks of a typicality and a 
numerus clausus of exclusive rights.
Consequently, the election of one of the main guiding 
elements of intellectual property emerges, by establishing 
the relationship between the forms of intellectual property 
and their corresponding legal protection - a proposition 
made by Tullio Ascarelli that constitutes the key to the 
classification of Biotechnology.
If one accepts the premise that there is legal protection 
for each form of manifestation of intellectual property, 
would the different aspects of Biotechnology be capable 
of deserving a unique and exclusive protection? This 
question will guide the guidelines of this research.
While the discipline of intellectual property is the 
most suitable means of protecting technology, since it is 
identified with the rights of the producers of technological 
knowledge, its advocates are taken into consideration only 
because they agree with the dominant theses of produ-
cing countries, who suffer almost decisive influence. And 
since it is strongly centralized, it tolerates only a stronger 
orientation of this concentration, claiming more effec-
tive consolidation and systematization on the part of all 
producers and leaving only the stigma of absorption or 
passive behavior a real stigma for the remaining countries.
The principal effect of this protection, which has 
exercised and continues to exert the most profound and 
lasting influence, is the special limit of industrial property 
rights as it is established, that is to say, by a state grant. 
An original and unparalleled experience is the general 
access of the population to the benefits associated with 
pharmaceutical development that gave its creators a power 
based on an instinct of domination that borders on the 
limits of state sovereignty, when at most it does not cool 
or weaken it.
A succession of events leads to the problem of concen-
tration of knowledge and occupies the center of the issues 
of the technology transfer system. It is also the main 
obstacle to be overcome. It has a demolishing function 
in the multiplication of knowledge to be disseminated, 
the territorial character of the rights of the exclusive 
constitutes the second major difficulty. Territoriality and 
its accompanying principle - the principle of territoria-
lity - affect most intellectual property rights, and more 
exclusively technology transfer. To understand this idea of 
territorial boundary, it is necessary to remember that the 
possibility of being exploited simultaneously in different 
parts of the world means that the high costs indicated 
to serve as a basis. And it is in this reality, neither ideal 
nor essential, that the adequate economic resources to 
meet these costs could enjoy the protection granted by 
the state.
In this regard, one can appreciate the difficulty in 
striking a balance between pharmaceutical interests, which 
argue about the need to obtain exclusive rights to what is 
developed in order to move forward with their research 
processes, and the interests of society at large, who need 
to have affordable medical treatments to deal with disea-
ses such as cancer and AIDS (Acquired Immunodeficiency 
Syndrome) at reasonable prices.
3.5 Imbalance in negotiating power of parties to a tech-
nology transfer agreement
The very form that for centuries has valued and pro-
tected the products of the intellect, and has served all 
those who have created or developed useful knowledge 
in their various types of protection around the world, 
has created barriers that, in combination with interna-
tional trade laws, generate true vertical line scales until 
economic development.
And the state of world commerce and the economy 
confines intellectual products into their basic categories: 
copyrights, patents, trademarks, business secrets, and 
new categories, which may well be represented by the 
integrated circuit, best known for its Anglophone chip 
version, about the solid tablet constituting and appearing.
This general scheme has been successful for its inten-
ded purpose, but it is unable to adapt the new known 
forms of creativity and innovation to other non-tech-
nology producing countries. It is sufficiently ingenious 
enough in its capacity for protection and guardianship, 
but proportionally moves on a world scale to transform 
other non-technology producing countries into mere 
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consumers and protectors of rights that, in reality, do 
not know in its essence or conception.
Technology does not flow in its knowledge, but in its 
use. And the effects it develops, while playing a facili-
tating role in the use of new and useful technology, do 
not stimulate bilateral trade growth, nor do they take full 
advantage of the pace of economic development.
By adopting this system of importing technology, an 
entire country submits itself to a perpetual costly econo-
mic dependency, and imposes a real disadvantage, to form 
an imbalance of the business parties that will play some 
positive role in the transfer of business, biotechnology, 
and technology in general.
3.6 The ways to carry out a biotechnological transfer
To resolve this situation, governmental and university 
scientific policies aimed at biotechnological projects in 
research and development should be encouraged. And the 
latter will result in a substantial increase in the number 
of scientific publications and an equivalent increase in 
the number of patents. Parallel to technology transfer, we 
should consider in this research that the restructuring of 
government policies for biotechnology should follow the 
following steps: (1) open access scientific publications, 
(2) scientific books, (3) patents; (4) related products to 
those on the market.
The choice of inventive activity has to be susceptible 
of industrial application, meeting the three basic legal 
requirements for patenting. The best example to illustrate 
the research is the most related case as a central research 
theme, which is the Chakrabarty case.
Although it is not a grandiose and exciting thesis to 
describe and classify biotechnological transference, any 
understanding of the use of the conceptual method has, 
beyond a wide space of argument, the possibility of being 
demonstrated. As the basis for all legal reasoning as to 
how the jurist would describe a transfer of biotechno-
logy, the first concepts extracted were exactly the abstract 
ones. It is necessary the memory developed precisely in 
the theoretical conception, in the first one worthy of 
repercussion about the biotechnological knowledge: the 
Chakrabarty case.
It is not possible, of course, to indicate the general 
characteristics that accompanied the debate and the 
development of the Chakrabarty case. Interpreting the 
developed phenomena, one can qualify some of the par-
ticular aspects of what happened. On March 17th, 1980, 
the United States Supreme Court voted, by the majority, 
to grant patent rights for a lineage of bacteria. The spe-
cies was of the genus Pseudomonas, a carrier of foreign 
DNA (deoxyribonucleic acid) segments, called plasmids, 
capable of conferring distinct genetic characteristics of 
what was naturally found in the bacterium.
This researcher, Ananda Chakrabarty, claimed to have 
“invented” a non-naturally occurring microorganism that 
exhibited important properties for general use, especially 
from improper oil spills, as it would have the ability to 
consume spilled oil.
This controversy was the initial milestone of legal 
studies on the importance of the patent system of living 
things and its contribution to biological technology, or 
more specifically to biotechnology. However, its contri-
bution goes far beyond the patent system itself, as it will 
take center stage in future problems of biotechnology 
transfer.
CONCLUSIONS
From the experience of a supposedly safe analysis, the 
main tendency proclaimed and disseminated by the most 
modern universities, both national and foreign, is manifested, 
to strive for the socio-political development of peoples, for 
the aggrandizement and dignity of the human person, in their 
most varied meanings, as, for example, in the research under-
taken resulting from the most rooted and truly fundamental 
problems between technology and biological development. 
The national process of technological evolution, dealt with 
in this particular research, went through certain stages that, 
despite being fast or slower, according to the difficult con-
ditions, did not at any time ignore the highly relevant level 
of activity related to technological promotion, the capacity 
of the national institutions and, of course, the effort against 
the development of the country.
The contrast between the anti-developmental forces - 
represented by the reaction to research and deliberate nonin-
vestment, coupled with the deficit of cadres - and those that 
excel in Brazil’s development - were not ignored, but rather 
treated as something that must be considered and evaluated 
as one of the manifestations of the tension between two 
true lines of action in the world economic policy. The most 
resistant means of elevating the progress and development 
of the country, or even of other countries, were considered 
in the research, especially by the aggressive orientation of 
large economic groups, in an attempt to prevent the process 
of technological liberation on a world scale. Developing coun-
tries - something not to be forgotten - are the main recipients 
of the actions of these ethnocentric groups organized in the 
form of multinational corporations, which at most reinforce 
concentrated wealth in their home countries and where they 
usually have your thirst.
From what is to be emphasized, it is evident that the 
internship was guided by the sense of achieving a balance 
between social interest and private interest, between the right 
of intellectual property owners and technological promotion. 
Proceeding in this reasoning, the research rejected what 
could be called the anachronistic character of the classical 
property model, either as a paradigm or as a source of rights 
involving technology, as well as the old and outdated liberal 
argument or a supposed absolute freedom to conduct or 
destination of knowledge and technology in the modern 
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economy, notwithstanding this statement exorbitated the 
object of the research carried out. To these liberal premises 
and without social purposes it is necessary to point out that 
the Constitution of the Republic removed the doubts that 
existed for Brazilian society regarding the results of tech-
nological research and its corresponding protection by the 
intellectual property regime: social interest and technological 
development must be observed and the economic status of 
the country (art. 5, XXIX).
The significance of the intellectual property in studies of 
technology transfer in general, moreover, must be stressed 
and exalted by scholars of biotechnology transfer. Despite 
the presence of distinct cognitive approaches, it was the 
professionals (intellectual property) who made it possible to 
construct a large theoretical framework (technology transfer), 
unparalleled in its dynamism. And in their classification, 
intellectual property scholars have elevated the contract to 
the most fertile field of the technology transfer application.
Two premises are required for the scattered fields of bio-
logical technology transfer. The first is that the significance 
of the work, appreciated by practical results, for the transfe-
rence that generates technology does not apply in absolute 
correspondence to the transference of biotechnology. It is 
that the dynamic focus of nature and life will be demanding 
a true system of its own for both.
From a dynamic point of view, the formation of living 
elements, such as microorganisms, which can reach the 
brink of evolutionary theories, does not fit in with the static 
and lifeless elements that normal mechanisms of technology 
transfer present or ordinarily use. Here, in this study, the 
old distinction between static and dynamic seems to have a 
direct and specific application.
This static-dynamic approach is the starting point for dis-
tinguishing the biological reactions of the technology studied 
here from those that fit with procedures that complement 
each other, such as machines, raw materials, and electricity.
Biotechnology transfer yet - or maybe always! It will 
require risks not known by the ability of living things to alter 
their own ways and to suffer external inflows of temperature 
and pressure. That is why the attempt to embrace biotechno-
logy by general technology and biotechnological transfer by 
technology meets limits. Thus, the influence of the successful 
theory of result obligations on technology transfer contracts 
does not harbor the biotechnology transfer contacts that will 
continue to be guarded by the environment obligation regime.
The elaboration of a new form of scientific knowledge 
based on an interdisciplinary view of biological knowledge 
for technology could generate special interest in demystifying 
the fundamental premise elaborated by Tullio Ascarelli, that 
there will be a tutelage for each form of manifestation of intel-
lectual property. Thus, Biotechnology would be determining 
a deviation in all knowledge built in our country, based on 
the works of Tullio Ascarelli.
It is in this regard that a question of exceptional impor-
tance arises as to the relationship between forms of intellectual 
property and their protection or legal protection. The combi-
ned succession of chemical and biological elements does not 
seem to us to create a new regime of scientific classification 
of intellectual property. Tullio Ascarelli’s proposition once 
again adds itself to the industrial property through its own 
understanding: they are isomorphic!
Isomorphism will be the formula of application in two-
-way correspondence to Biotechnology and Chemistry and 
Pharmaceuticals, because they are complex structures in 
their entities and which apply to each other, indistinctly, like 
parts with a similar role in their structures. Notwithstanding 
the complexity of the biological elements, Tullio Ascarelli’s 
statement is not inconsistent with the discoveries of biote-
chnology, but stands with its own feet.
In other words, the key to the success of the theories 
developed by Tullio Ascarelli lies in the fact that he correctly 
captured the protection of the intellectual property, without 
prejudice to the complications of the phenomena studied 
by the different areas of knowledge and that are capable of 
deserving protection by the intellectual property protection.
This leads to the conclusion that the non-application of the 
result obligation in correspondence of the general technology 
transferred to biotechnology and the non-separation between 
Ascarelli’s work and protected and transferred biotechnology 
are concluded.
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